Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Asparaginase Articles

PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app

12 January 2009

Enzon gets Orphan Drug status for new version of Oncaspar

6 October 2008

Enzon Pharma explores options, including the sale of its specialty drugs unit

18 August 2008

Eight drugs get nod from EMEA's COMP

21 July 2008

EUSA divests MAb and other research

12 May 2008

EMEA issues its first opinions on PIPs; six waivers adopted, may review process

14 January 2008

New transatlantic Pharma launches

12 March 2007

Enzon swings to $286M loss in 4th-qtr 2005

13 March 2006

Merck & Co rapped over asparaginase plant

8 August 2005

NPS Pharma and Enzon to merge in $1.6B deal; aim to be "a new biotech leader"

3 March 2003

Enzon - improving the delivery and side effect profile of proven

20 January 1999

Progress Revealed At Enzon

9 December 1996

Medac To Market Enzon's Oncaspar In Europe And Russia

21 October 1996

R-PR Receives Approval In Canada

26 September 1994

ENZON'S ONCASPAR APPROVED IN USA

14 February 1994

ENZON GETS APPROVABLE RECOMENDATION

13 December 1993

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS